微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 66.39% | 0.87% | 0.56% | 38/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 66.02% | 0.08% | 1.63% | 38/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 64.96% | 0.45% | -0.75% | 37/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 65.45% | 2.15% | -0.55% | 42/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 65.81% | 2.94% | -0.23% | 41/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 65.96% | 2.92% | 1.99% | 41/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 64.67% | 2.54% | 0.93% | 38/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 64.08% | -0.93% | 0.23% | 43/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 63.93% | -2.41% | -0.25% | 42/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 64.09% | -1.74% | 1.61% | 44/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 63.07% | -4.65% | -2.48% | 44/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 64.68% | -0.11% | -1.27% | 48/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 65.51% | -0.45% | 0.44% | 47/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 65.22% | -1.06% | -1.4% | 48/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 66.15% | -0.49% | 2.17% | 44/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 64.75% | -0.51% | -1.62% | 53/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 65.81% | -0.51% | -0.17% | 43/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 65.92% | -0.08% | -0.84% | 47/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 66.48% | 2.5% | 2.15% | 35/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 65.08% | 1.91% | -1.61% | 49/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 66.14% | 2.24% | 0.26% | 39/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 65.97% | 1.68% | 1.71% | 39/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 64.86% | -0.21% | 1.57% | 36/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 63.86% | 2.86% | -1.3% | 48/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 64.7% | 3.29% | -0.28% | 35/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 64.88% | 3.69% | -0.18% | 39/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 64.99% | 0.97% | 4.69% | 30/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 62.08% | -2.78% | -0.88% | 47/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 62.64% | -3.88% | 0.1% | 35/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 62.57% | -3.49% | -2.79% | 37/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 64.37% | -1.91% | 0.8% | 31/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 63.86% | -0.36% | -2% | 36/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 65.17% | 0.86% | 0.51% | 25/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 64.84% | 1.01% | -1.2% | 21/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 65.62% | 2.07% | 2.39% | 17/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 64.09% | 4.89% | -0.8% | 26/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 64.61% | 5.28% | 0.66% | 18/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 64.19% | 4.92% | -0.16% | 20/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 64.29% | 3.88% | 5.22% | 16/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 61.1% | -0.4% | -0.43% | 26/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 61.37% | -0.72% | 0.31% | 18/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 61.17% | -1.38% | -1.15% | 20/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 61.89% | 2.43% | 0.88% | 17/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |